On 27 July 2020 the company had announced the receipt of an approval of XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA by the U.S. Food and Drug Administration (USFDA). Such approval triggered the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty. which is included in the above mentioned award and has already been accounted for and charged off in the companys financial statements for the financial year 2020-21.
Dr. Reddys Laboratories said that it is exploring all legal options to challenge the award.
Dr Reddys Laboratories is an integrated pharmaceutical company. Through its three businesses - pharmaceutical services & active ingredients, global generics and proprietary Products.
On a consolidated basis, Dr Reddys Laboratories net profit dropped 28% to Rs 553.50 crore on 7% increase in revenues to Rs 4,728.40 crore in Q4 March 2021 over Q4 March 2020.
Powered by Capital Market - Live News